• Policy
• Hemlibra's benefit speeds up to strengthen accessibility
• by Lee, Jeong-Hwan Oct 17, 2022 06:03am

• Company
• Pfizer Korea leaves its beloved 15-year Myeongdong office
• by Eo, Yun-Ho Oct 14, 2022 05:53am

• Company
• Xofluza, is aiming for a rebound in sales
• by Oct 14, 2022 05:53am

• Policy
• Proposal for improvement of omission of PE data submission
• by Lee, Jeong-Hwan Oct 14, 2022 05:53am

• Policy
• CDDC blindly opposes applying RSA to Tabrecta and Rybrevant
• by Lee, Jeong-Hwan Oct 14, 2022 05:53am

• Company
• PARP anticancer drugs raise expectations of ovarian cancer
• by Oct 14, 2022 05:53am

• Company
• The release of a flu vaccine exclusively for the elderly
• by Oct 13, 2022 06:09am

• Company
• How about collaboration?
• by Kim, Jin-Gu Oct 13, 2022 06:09am

• Company
• Dupixent's child benefit expands after over 1 1/2 yrs
• by Eo, Yun-Ho Oct 13, 2022 06:08am

• Company
• Status of antidiabetic SGLT-2 inhibitors rise with use in HF
• by Oct 13, 2022 06:08am